Nearly 40% of patients with advanced stomach cancer were still alive three years on with a new drug pairing

For people whose stomach or gastroesophageal cancer has spread and is driven by a protein called HER2, options have long been limited. In a 914-person trial spanning more than 30 countries, adding the antibody drug Ziihera (zanidatamab) and the immunotherapy tislelizumab to chemotherapy helped patients live a median of 27 months, versus 19.6 months on standard treatment — and 39.8% were still alive after three years, compared with 22.9%. The results, led by Dr Kohei Shitara of Japan's National Cancer Center Hospital East, were presented at the ESMO congress.

SDG 3 · Good health and well-being — Mechanism: tech innovation